Dr Maria De Santis speaks to ecancer about the final results from the POTOMAC trial on durvalumab (D) in combination with Bacillus Calmette-Guérin (BCG) for BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC).

The trial randomised patients into three arms - one year of durvalumab plus BCG induction and maintenance, one year of durvalumab plus BCG induction only and BCG induction maintenance as the control arm. The first endpoint was disease-free survival.

Dr De Santis reports that results support one year of durvalumab in addition to BCG induction and maintenance therapy as a new treatment option in high-risk NMIBC.